October 29, 2024 02:26 PM EDT
R&D

Coya shares sink on Phase 2 Alzheimer's da­ta for de­pri­or­i­tized drug

Max Gelman

Senior Editor

Coya Ther­a­peu­tics’ stock price $COYA fell more than 20% on Tues­day af­ter the com­pa­ny re­port­ed Phase 2 da­ta for its Alzheimer’s dis­ease pro­gram, called COYA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times